APRE

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, focused on advancing innovative cancer therapies by targeting the reactivation of the mutant p53 tumor suppressor protein, which plays a critical role in tumor suppression. With a diverse pipeline aimed at multiple cancer indications, Aprea is poised to make a substantial impact on the oncology market. The company’s unique therapeutic approach, combined with a steadfast dedication to enhancing patient outcomes, positions it as an appealing investment opportunity for institutional investors looking to support the next wave of healthcare breakthroughs.